KR102792441B1 - ＦｃＲｎ 항체 및 이의 사용 방법 - Google Patents

ＦｃＲｎ 항체 및 이의 사용 방법 Download PDF

Info

Publication number
KR102792441B1
KR102792441B1 KR1020227045647A KR20227045647A KR102792441B1 KR 102792441 B1 KR102792441 B1 KR 102792441B1 KR 1020227045647 A KR1020227045647 A KR 1020227045647A KR 20227045647 A KR20227045647 A KR 20227045647A KR 102792441 B1 KR102792441 B1 KR 102792441B1
Authority
KR
South Korea
Prior art keywords
seq
amino acid
cdr
acid sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227045647A
Other languages
English (en)
Korean (ko)
Other versions
KR20230007545A (ko
Inventor
매럴린 커리
데이빗 제이. 킹
레오나 이. 링
제임스 3세 미도르
슈카리타 로이
앤서니 매닝
Original Assignee
모멘타 파머슈티컬스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 모멘타 파머슈티컬스 인코포레이티드 filed Critical 모멘타 파머슈티컬스 인코포레이티드
Priority to KR1020257010788A priority Critical patent/KR20250052465A/ko
Publication of KR20230007545A publication Critical patent/KR20230007545A/ko
Application granted granted Critical
Publication of KR102792441B1 publication Critical patent/KR102792441B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
KR1020227045647A 2015-01-30 2016-01-29 ＦｃＲｎ 항체 및 이의 사용 방법 Active KR102792441B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257010788A KR20250052465A (ko) 2015-01-30 2016-01-29 ＦｃＲｎ 항체 및 이의 사용 방법

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562110071P 2015-01-30 2015-01-30
US62/110,071 2015-01-30
US201562258082P 2015-11-20 2015-11-20
US62/258,082 2015-11-20
KR1020177024165A KR102483016B1 (ko) 2015-01-30 2016-01-29 ＦｃＲｎ 항체 및 이의 사용 방법
PCT/US2016/015720 WO2016123521A2 (en) 2015-01-30 2016-01-29 Fcrn antibodies and methods of use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020177024165A Division KR102483016B1 (ko) 2015-01-30 2016-01-29 ＦｃＲｎ 항체 및 이의 사용 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257010788A Division KR20250052465A (ko) 2015-01-30 2016-01-29 ＦｃＲｎ 항체 및 이의 사용 방법

Publications (2)

Publication Number Publication Date
KR20230007545A KR20230007545A (ko) 2023-01-12
KR102792441B1 true KR102792441B1 (ko) 2025-04-08

Family

ID=56544538

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020227045647A Active KR102792441B1 (ko) 2015-01-30 2016-01-29 ＦｃＲｎ 항체 및 이의 사용 방법
KR1020177024165A Active KR102483016B1 (ko) 2015-01-30 2016-01-29 ＦｃＲｎ 항체 및 이의 사용 방법
KR1020257010788A Pending KR20250052465A (ko) 2015-01-30 2016-01-29 ＦｃＲｎ 항체 및 이의 사용 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020177024165A Active KR102483016B1 (ko) 2015-01-30 2016-01-29 ＦｃＲｎ 항체 및 이의 사용 방법
KR1020257010788A Pending KR20250052465A (ko) 2015-01-30 2016-01-29 ＦｃＲｎ 항체 및 이의 사용 방법

Country Status (21)

Country Link
US (3) US10676526B2 (enExample)
EP (2) EP4286011A3 (enExample)
JP (2) JP6853178B2 (enExample)
KR (3) KR102792441B1 (enExample)
CN (13) CN118667011A (enExample)
AU (2) AU2016211280B2 (enExample)
DK (1) DK3250610T3 (enExample)
ES (1) ES2962824T3 (enExample)
FI (1) FI3250610T3 (enExample)
HR (1) HRP20231399T1 (enExample)
HU (1) HUE063778T2 (enExample)
IL (1) IL252837B (enExample)
LT (1) LT3250610T (enExample)
NZ (1) NZ772383A (enExample)
PL (1) PL3250610T3 (enExample)
PT (1) PT3250610T (enExample)
RS (1) RS64768B1 (enExample)
SG (2) SG11201705475QA (enExample)
SI (1) SI3250610T1 (enExample)
SM (1) SMT202300365T1 (enExample)
WO (1) WO2016123521A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2934644C (en) 2013-12-24 2023-11-21 Argen-X N.V. Fcrn antagonists and methods of use
RU2714153C2 (ru) * 2014-06-12 2020-02-12 Ф. Хоффманн-Ля Рош Аг СПОСОБ ОТБОРА АНТИТЕЛ С МОДИФИЦИРОВАННЫМ ВЗАИМОДЕЙСТВИЕМ С FcRn
CN118667011A (zh) 2015-01-30 2024-09-20 动量制药公司 Fcrn抗体及其使用方法
DK3491025T3 (da) 2016-07-29 2024-01-15 Momenta Pharmaceuticals Inc Fcrn-antistoffer og anvendelsesmetoder heraf
MA49378A (fr) * 2017-06-15 2020-04-22 UCB Biopharma SRL Méthode de traitement de la thrombocytopénie immunitaire
BR112020011483A2 (pt) 2017-12-08 2020-11-24 Argenx Bvba uso de antagonistas de fcrn para tratamento de miastenia gravis generalizada
AU2018386193B2 (en) * 2017-12-13 2025-04-24 Momenta Pharmaceuticals, Inc. FcRn antibodies and methods of use thereof
MY209122A (en) 2018-06-08 2025-06-23 argenx BV Compositions and methods for treating immune thrombocytopenia
CR20210088A (es) * 2018-07-20 2021-09-02 Momenta Pharmaceuticals Inc Composiciones de anticuerpos fcrn y métodos de uso de estos
CA3106670A1 (en) * 2018-07-20 2020-01-23 Momenta Pharmaceuticals, Inc. Fcrn antibody compositions
KR20210078517A (ko) 2018-10-16 2021-06-28 유씨비 바이오파마 에스알엘 중증근무력증의 치료 방법
BR112021024632A2 (pt) 2019-06-07 2022-01-18 Argenx Bvba Formulações farmacêuticas de inibidores de fcrn adequados para administração subcutânea
US20220259308A1 (en) * 2019-08-01 2022-08-18 Janssen Biotech, Inc. Fcrn antibodies and methods of use thereof
JP7722991B2 (ja) * 2019-11-19 2025-08-13 イミュノバント・サイエンシズ・ゲーエムベーハー 抗ｆｃｒｎ抗体を用いた温熱自己免疫性溶血性貧血の治療方法
EP4454711A3 (en) 2020-01-08 2025-01-08 argenx BV Methods for treating pemphigus disorders
WO2022098955A1 (en) * 2020-11-06 2022-05-12 Janssen Biotech, Inc. Fcrn antibodies and methods of use thereof
US20240081301A1 (en) * 2021-02-02 2024-03-14 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric fcrn
CN117693523A (zh) * 2021-08-13 2024-03-12 舒泰神（北京）生物制药股份有限公司 特异性识别fcrn的抗体及其用途
WO2023030501A1 (zh) * 2021-09-03 2023-03-09 舒泰神（北京）生物制药股份有限公司 特异性识别FcRn的抗体及其应用
CA3254741A1 (en) 2022-05-30 2023-12-07 Hanall Biopharma Co., Ltd. ANTI-FCRN ANTIBODY OR ANTIGEN-BINDING FRAGMENT OF FCRN EXHIBITING IMPROVED STABILITY
EP4540283A1 (en) 2022-06-15 2025-04-23 argenx BV Fcrn/hsa binding molecules and methods of use
CN120693177A (zh) 2023-02-04 2025-09-23 动量制药公司 用于治疗胎儿和新生儿溶血性疾病的组合物和方法
TW202527982A (zh) 2023-09-11 2025-07-16 美商默門塔醫藥公司 Fcrn抗體之醫藥組成物
WO2025099576A1 (en) 2023-11-06 2025-05-15 Momenta Pharmaceuticals, Inc. Compositions and methods for treating rheumatoid arthritis
WO2025163617A1 (en) 2024-02-04 2025-08-07 Momenta Pharmaceuticals, Inc. Compositions and methods for treating sjögren's disease
WO2025186787A1 (en) 2024-03-08 2025-09-12 Momenta Pharmaceuticals, Inc. Compositions and methods for treating fetal and neonatal alloimmune thrombocytopenia

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60334678D1 (de) 2002-02-14 2010-12-09 Chugai Pharmaceutical Co Ltd Antikörper enthaltende pharmazeutische lösungen
WO2005013912A2 (en) * 2003-08-08 2005-02-17 The Research Foundation Of State University Of Newyork Anti-fcrn antibodies for treatment of auto/allo immune conditions
US7662928B2 (en) 2003-08-08 2010-02-16 The Research Foundation Of State University Of New York Anti-FcRn antibodies for treatment of auto/allo immune conditions
CN101124245A (zh) * 2003-11-12 2008-02-13 比奥根艾迪克Ma公司 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法
WO2006096490A2 (en) 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc ANTI-MAdCAM ANTIBODY COMPOSITIONS
JP2009524664A (ja) 2006-01-25 2009-07-02 ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク 自己／アロ免疫疾患の治療のための抗−ｆｃｒｎ抗体
CN101421297A (zh) * 2006-02-17 2009-04-29 森托尼克斯制药有限公司 阻断lgG对FcRn的结合的肽
EP2004690A2 (en) 2006-03-13 2008-12-24 Ablynx N.V. Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
EP2310415B8 (en) 2008-04-25 2017-12-13 Dyax Corp. Antibodies against fcrn and use thereof
JP5683581B2 (ja) * 2009-06-30 2015-03-11 リサーチ ディベロップメント ファウンデーション 免疫グロブリンＦｃポリペプチド
EP2966089B1 (en) * 2011-06-02 2020-03-25 Dyax Corp. Fc receptor binding proteins
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
US20130323242A1 (en) 2012-06-01 2013-12-05 Ophthotech Corp. Compositions comprising an anti-pdgf aptamer and a vegf antagonist
US9844594B2 (en) 2012-12-18 2017-12-19 Merck Sharp & Dohme Corp. Liquid formulations for an anti-TNF α antibody
ES2802274T3 (es) 2013-05-02 2021-01-18 Momenta Pharmaceuticals Inc Glicoproteínas sialiladas
KR101815265B1 (ko) 2013-06-20 2018-01-04 한올바이오파마주식회사 FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
CN118667011A (zh) 2015-01-30 2024-09-20 动量制药公司 Fcrn抗体及其使用方法
US20160264669A1 (en) * 2015-03-09 2016-09-15 Argen-X N.V. Methods of reducing serum levels of fc-containing agents using fcrn antagonists
KR20180023900A (ko) 2015-05-12 2018-03-07 신티뮨, 인크. 인간화된 친화성 성숙 항-FcRn 항체
DK3491025T3 (da) 2016-07-29 2024-01-15 Momenta Pharmaceuticals Inc Fcrn-antistoffer og anvendelsesmetoder heraf
BR112020011483A2 (pt) 2017-12-08 2020-11-24 Argenx Bvba uso de antagonistas de fcrn para tratamento de miastenia gravis generalizada
AU2018386193B2 (en) 2017-12-13 2025-04-24 Momenta Pharmaceuticals, Inc. FcRn antibodies and methods of use thereof
CA3106670A1 (en) 2018-07-20 2020-01-23 Momenta Pharmaceuticals, Inc. Fcrn antibody compositions
CR20210088A (es) 2018-07-20 2021-09-02 Momenta Pharmaceuticals Inc Composiciones de anticuerpos fcrn y métodos de uso de estos

Also Published As

Publication number Publication date
PL3250610T3 (pl) 2024-01-29
BR112017015287A2 (pt) 2018-01-16
AU2022201145B2 (en) 2024-11-14
CN107567460B (zh) 2021-04-23
KR20230007545A (ko) 2023-01-12
US20180016334A1 (en) 2018-01-18
JP2018504907A (ja) 2018-02-22
CN118667009A (zh) 2024-09-20
PT3250610T (pt) 2023-11-13
CN118667012A (zh) 2024-09-20
CN118667015A (zh) 2024-09-20
CN113384693A (zh) 2021-09-14
CN118667011A (zh) 2024-09-20
EP3250610A4 (en) 2018-08-22
RS64768B1 (sr) 2023-11-30
ES2962824T3 (es) 2024-03-21
US20200299382A1 (en) 2020-09-24
CN118562003A (zh) 2024-08-30
SG10202007232WA (en) 2020-09-29
EP3250610A2 (en) 2017-12-06
CN118638230A (zh) 2024-09-13
KR102483016B1 (ko) 2023-01-03
DK3250610T3 (da) 2023-10-30
CN118667014A (zh) 2024-09-20
LT3250610T (lt) 2023-09-25
US10676526B2 (en) 2020-06-09
CN118667013A (zh) 2024-09-20
CN118652337A (zh) 2024-09-17
CN118667010A (zh) 2024-09-20
JP2021061854A (ja) 2021-04-22
SI3250610T1 (sl) 2023-11-30
SMT202300365T1 (it) 2023-11-13
FI3250610T3 (fi) 2023-11-01
SG11201705475QA (en) 2017-08-30
JP7224382B2 (ja) 2023-02-17
AU2022201145A1 (en) 2022-03-17
IL252837B (en) 2021-10-31
CN107567460A (zh) 2018-01-09
HRP20231399T1 (hr) 2024-02-16
EP4286011A3 (en) 2024-02-14
AU2016211280A1 (en) 2017-07-13
CN118638229A (zh) 2024-09-13
IL252837A0 (en) 2017-08-31
CA2972822A1 (en) 2016-08-04
KR20250052465A (ko) 2025-04-18
NZ733097A (en) 2024-07-05
KR20170109020A (ko) 2017-09-27
CN113384693B (zh) 2025-07-04
US20240158508A1 (en) 2024-05-16
EP4286011A2 (en) 2023-12-06
NZ772383A (en) 2024-11-29
JP6853178B2 (ja) 2021-03-31
WO2016123521A2 (en) 2016-08-04
US11732047B2 (en) 2023-08-22
HUE063778T2 (hu) 2024-01-28
EP3250610B1 (en) 2023-08-09
AU2016211280B2 (en) 2021-11-25
WO2016123521A3 (en) 2016-09-22

Similar Documents

Publication Publication Date Title
AU2022201145B2 (en) FcRn antibodies and methods of use thereof
US20230049725A1 (en) FcRn Antibodies and Methods of Use Thereof
JP2014509325A (ja) 拮抗性ｄｒ３リガンド
CA2972822C (en) Fcrn antibodies and methods of use thereof
HK40103769A (en) Fcrn antibodies and methods of use thereof
HK1247218B (en) Fcrn antibodies and methods of use thereof
HK1247218A1 (en) Fcrn antibodies and methods of use thereof
BR122021007991B1 (pt) Uso de anticorpos que se ligam a fcrn humana
BR112017015287B1 (pt) Anticorpos isolados que se ligam a fcrn humano, e composição farmacêutica
KR20200098604A (ko) FcRn 항체 및 이의 사용 방법

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20221226

Application number text: 1020177024165

Filing date: 20170829

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240219

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20241010

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250102

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250402

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250403

End annual number: 3

Start annual number: 1

PG1601 Publication of registration